-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Chemours, Lowers Price Target to $16

Benzinga·10/05/2026 19:58:53
語音播報
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $18 to $16.